Research programme: cell cycle inhibitors - Cyclacel Pharmaceuticals/CV Therapeutics
Alternative Names: Cell cycle inhibitors research programme - Cyclacel Pharmaceuticals/CV TherapeuticsLatest Information Update: 03 Mar 2006
At a glance
- Originator CV Therapeutics; Cyclacel
- Class
- Mechanism of Action Cyclin-dependent kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Mar 2006 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 03 Mar 2006 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 23 Jan 2001 Preclinical development for Cancer in United Kingdom (Unknown route)